Hot Mandates: US-Based Impact Investor

22 Feb

The fund is a $350M specialist venture capital fund based in Boston, MA and London, UK. The fund was founded in 2015 with the vision of delivering high-impact therapeutics for age-related dementia. The fund is looking to invest in therapeutics to treat all forms of dementia, including Alzheimer’s Disease (AD), Parkinson’s Disease Dementia (PDD), Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), and Huntington’s Disease (HD). The fund will invest in all stages, but prefers to invest in companies with novel therapeutics, and supports the companies through multiple rounds to an exit, investing $15-25M over the life of a company. The fund is willing to invest globally.

The fund is open to all forms of therapeutics and has a focus on five scientific themes: neuroinflammation, proteostasis, synaptic physiology, genomic instability, and platform technologies. However, the fund is always open to new scientific approaches for treatments and is willing to consider all mechanisms of action.

The fund is open to leading, or following, and takes a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: